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Background: Schizophrenia is a severe psychotic disorder characterized by significant disturbances in thinking,
perception, emotions and behavior. Even if it is not a very frequent disorder, but it is the most burdensome and
costly illnesses worldwide. The total population was approximate 1.3 billion and there are approximate 8 million
schizophrenic patients in China. Despite the wide-ranging financial and social burdens associated with
schizophrenia, but there have been few cost-of-illness studies of this illness in China.
Objective: To evaluate the economic cost of schizophrenic patients in China.
Methodology: 356 schizophrenic patients who met with DSM-IV criteria were enrolled and investigated with the
Economic Burden Questionnaire(EBQ), 299 schizophrenic patients completed the study for 12 months. All the data
were combined and classified by researcher. EBQ include all kinds of cost such as direct cost, indirect cost and total
cost as well. It was filled in by patients and their close caregivers. Comparison of cost was made between not only
out-patients and in-patients but also urban patients and rural patients. Multiple stepwise regression analysis was
made to identify the main influence factors of total cost.
Results: (i) The per case per annum total costs, direct costs and indirect costs of schizophrenia amounted to US
$2586.21, US$862.81(33.4%) and US$1723.40(66.6%) respectively. The per case total cost, direct cost and direct
medical cost of in-patients were more higher than out-patients (P < 0.05). (ii) There was significant difference in per
case per annum total cost, direct cost, direct medical cost, cost due to lost working-days and disability between
urban and rural schizophrenic patients (P < 0.05), the former is higher than the latter. (iii) The results of multivariate
stepwise regression analysis show that five variables were significantly correlated with higher cost: professional
status(cadre), diagnostic subtype(residual schizophrenia), urban or rural patients(urban patients), in-patients or
out-patients(in-patients) and researcher centre(southern center). The standardized regression coefficient were 0.308,
0.218, 0.212, 0.156 and 0.149 respectively, the correlation of determination R square was 0.2741, F = 15.651,
P < 0.0000. These characteristics explain 27.41% of the variability in the total cost.
Conclusion: (i) Economic cost of schizophrenia were serious, we must pay close attention to it. (ii) The indirect cost
are the majority of the total cost. The cost of urban patients are more higher than the cost of rural patients, the
cost of in-patients are more higher than the cost of out-patients.
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Schizophrenia is a chronic, devastating mental disorder
characterized by distortions of thinking and perception.
About 1.1 percent of the population age 18 and older have
schizophrenia. It is very costly for families and society.
The expensive costs of schizophrenia imposes a disease
burden on themselves, health care providers, their families
and the wider society [1-4]. The total economic burden of
schizophrenia is comparable to the total costs of any other
mental disorder. In most of the developed countries,
current healthcare expenditure on schizophrenia accounts
for 1.6% to 2.5% of the total healthcare budget [5,6].
Schizophrenia is a chronic mental illness associated with a
significant and long-lasting health, social, and financial
burden due to expenditures for hospitalization, treatment
and rehabilitation, reduced and lost productivity [5-10].
The treatment for schizophrenia is still a major clinical
challenge to psychiatrists. The characterized psychotic
symptoms of schizophrenia such as hallucination and
delusion, inappropriate affect, loss of association induced
the treatments more complex. The prognosis of schizo-
phrenia is poor for at least one third of patients. Schizo-
phrenia patients have a higher risk of comorbidity and
social exclusion and the mortality rate is more than
twice that in the overall population. As a result, schizo-
phrenia is the most costly psychiatric illness currently
[10]. An Italian study showed that the monthly service
costs per patient was nearly double that for patients with
other diagnoses. Non-service costs associated with pa-
tients’ lack of job opportunities were more than three
times higher for schizophrenic patients [11].
International cost of illness (COI) studies for schizo-
phrenia show a wide variation of annual costs [12-16].
Mangalore’s study investigated the costs of schizophrenia
in England in 2004/2005. The estimated total societal
cost of schizophrenia was 6.7 billion pounds. The direct
cost of treatment and care was about 2 billion pounds;
the indirect cost to the society was huge, amounting to
nearly 4.7 billion pounds. The cost of lost productivity
due to unemployment, absence from work and prema-
ture mortality of patients was 3.4 billion pounds. Cost of
informal care and private expenditures borne by families
was 615 million pounds. The cost of lost productivity of
caregivers was 32 million pounds. Estimated cost to the
criminal justice system was about 1 million pounds. It is
estimated that about 570 million pounds will be paid out
in benefit payments and the cost of administration asso-
ciated with this is about 14 million pounds [12].
In Canada, Goeree used a prevalence-based cost-of-
illness (COI) approach to estimate the financial burden
of schizophrenia in 2004. Results showed that the direct
healthcare and non-healthcare costs were estimated to
be 2.02 billion Canadian dollars (CAN dollars) in 2004.
There were 374 deaths attributed to schizophrenia. Thecost of lost productivity due to unemployment, absence
from work and an additional productivity morbidity es-
timate of 4.83 billion CAN dollars, for a total cost esti-
mate of 6.85 billion CAN dollars. The largest part of
the total cost estimate was for productivity losses asso-
ciated with morbidity in schizophrenia (70% of total
costs). Their results also showed that total cost esti-
mates were most sensitive to alternative assumptions
regarding the additional unemployment due to schizo-
phrenia [13].
In Australia [14], Carr estimated the costs of psych-
osis, most of the patients were schizophrenic patients.
His results showed that annual societal costs for the
average patient are of the order of 46,200 Australian
dollars, 27,500 Australian dollars in lost productivity,
13,800 Australian dollars in inpatient mental health care
costs and 4900 Australian dollars in other costs. The
total economic cost in Australia was at least 1.45 billion
Australian dollars per annum. The societal costs are at
least 2.25 billion Australian dollars per annum. The so-
cietal cost due to schizophrenia was at least 1.44 billion
Australian dollars.
Schizophrenia accounts for 2.5% of total health care
expenditures in the US. The cost of all mental illness in
the US has been estimated at US$103.7 billion, of which
schizophrenia alone accounts for US$22.7 billion [15].
Lee investigated the economic costs of outpatients
with schizophrenia in Taiwan China, and surveyed the
influence factors of costs. The average annual total cost
was approximately US$16,576 per patient. The direct
and indirect costs were 13% and 87% of the total costs,
respectively, the indirect costs were higher than the dir-
ect costs. The productivity loss of both the patients and
their caregivers was the major component of the indir-
ect costs. The main influence factors of costs were pa-
tient’s age, global functions, severity of extrapyramidal
symptoms, type of antipsychotics and patient’s illness
duration [16].
The total population was approximate 1.3 billion in
China. There are approximate 8 million schizophrenic
patients in China [17]. Despite the wide-ranging finan-
cial and social burdens associated with schizophrenia,
there have been few cost-of-illness studies of this illness
in China.
The present paper aims at: (i) evaluating per case per
annum total economic costs, direct costs and indirect
costs of schizophrenia using a bottom-up approach; (ii)
comparing the differences of the cost between in-patients
and out-patients; (iii) comparing the difference of the cost
between urban-patients and rural-patients; (iv) empirically
determining the explanatory variables of total cost varia-
tions. The final purpose being that of offering useful infor-
mation to policies makers and highlighting the economic
importance of schizophrenia.
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Study design and patients
The present study is a prospective prevalence-based
[12,18] multi-centre COI observational study analyzing
costs in a sample of patients with schizophrenia in two
areas of China (main land). The period of study was of
12 months and referred to 2010. Two centers took part
in the project; one from northern China and another
from southern China. All participants were out-patients
or in-patients with schizophrenia from the two centers.
The northern researcher centre is an affiliated hospital
of Jining Medical University in Shandong Province, it’s
main catchment area is Shandong Province and surround-
ing area. The southern researcher centre is an affiliated
hospital of Central South University in Hunan Province.
It’s main catchment area is Hunan Province and sur-
rounding area. The two centers were all psychiatric hospi-
tals treating various mental disorders and covered by
similar insurance model of China.
Patients eligible for the study had a diagnosis of
schizophrenia, defined according to the Diagnostic and
Statistical Manual of Mental Disorders-fourth edition
(DSM-IV) criteria.
Each centre required to recruit patients, meeting the
inclusion and exclusion criteria.
Inclusion criteria were:
i. Meet with the diagnostic criteria of schizophrenia of
DSM-IV;
ii. Age between 16 and 65 years old;
iii. There is one caregiver at least and knew well the
information of the illness, treatment and costs
during the period of study;
iv. No plan to emigrate during the period of study;
v. Age of caregiver is more than 18 years old,
educational time is more than 5 years, caregiver can




i. With serious physical disease;
ii. Information is not particular or not credible;
iii. Plan to emigrate in 1 year;
iv. The caregiver is suffering from mental disorder;
v. Drug or alcohol abusers.
Each of the centers provided the list of all patients
meeting the inclusion and exclusion criteria. Researchers
selected patients randomly according to random number
chart and inclusion criteria. 356 schizophrenic patients
were enrolled and 299 schizophrenic patients completed
the study and their data was integrated. 57 case of patientsdrop out for different reasons, 28 revoked the informed
consent, 12 had concurrent illness, 5 emigrated, 12 could
not provide complete information.
Cost estimates
Specifically instruments EBQ were design to collect data
and measure costs. EBQ consisted of Part A and Part B,
Part A gathered data on: (1) socio-demographic data re-
ferred to gender, age and marriage as well; and (2)
clinical data referred to duration of illness, diagnostic
subtype, time in contact with hospital, previous hospi-
talizations in mental hospitals as well. Part B gathered
data on: economic costs and time costs and other re-
sources use as well.
Part A was filled by psychiatrists who followed up the
patients during the period of study. Part B was submit-
ted by psychiatrist to the patients’ main caregiver (usu-
ally a close relative) who filled Part B.
Cost components
The total cost components included in the present study
can be classified as direct costs and indirect costs.
Direct costs components concerned:
i. Direct medical costs–treatment costs and other
costs of medical services;
ii. Direct non-medical costs–all other resource use re-
lated to a disease.
iii. Indirect costs components concerned:
(i) Value of damaged properties;
(ii) The costs due to lost working-days and disability
incurred by patients and caregivers;
(iii) Mortality costs–loss of productivity to suicide
and related mortality.Measurement of costs
A bottom-up approach [12,18,19] was used to measure
costs data on resources use were gathered prospectively.
As to the indirect costs, the human capital approach
(HCP) [18] was used to estimate production losses due
to illness. The dead cases because of schizophrenia were
collected and analyzed, The dead cases for other reasons
were eliminated. We used the average wages of local
population to evaluate losses of production.
Analysis of data
To analyze per case per annum total costs, direct costs, in-
direct costs and the proportion of each part. To compare
the differences of the cost not only between in-patients
and out-patients but also between urban-patients and
rural-patients, to determine the explanatory variables of
cost variations. As variables were not normally distributed,
we used the non-parameter Mann–Whitney U test.





Gender Male 181 60.5
Female 118 39.5
Education Primary 46 15.
Junior 131 43.8




Marriage Married 110 36.8
Unmarried 150 50.2
Others 39 13.0
















Urban patient 118 36.1








Center Northern 162 54.2
Southern 137 45.8
Age - 16 ~ 65 years (31.41 ± 11.33)
years
Episode age - 12 ~ 61 years (25.45 ± 9.83)
years
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tify the factors that could explain the variability of aver-
age total cost of a patient. As regressions of total cost we
used the following socio-demographic and medical vari-
ables recorded in our questionnaire.
Demographic variable (sex, age, episode age, marital
status, etc.);
Socio-economic variable (family status, education, pro-
fessional status, etc.);
Geographic variable;
Clinical variable and variable related with illness (diagnos-
tic subtype, duration of illness, in-patient or out-patient,
urban-patient or rural-patient, etc.).
Because total cost had a slightly skewed distribution, a
logarithmic transformation was used in analyzing the re-
lationship between total cost and the other independent
variables. Thus the dependent variable presented an ap-
proximately normal distribution. Polytomous variables (i.e.
discrete variables which have more then two options) like
occupational status, educational status and diagnostic sub-
type were transformed into dummy variable.
All variables were entered into a stepwise backward
regression model, the final model being that which of-
fered the best explanation for total costs, using the set of
available variables.




Sample characteristics are presented in Table 1.
Total cost, direct cost and indirect cost
The per case per annum total cost, direct cost and indir-
ect cost are shown in Table 2.
Average annual total cost per patient was of US$
2586.21, the per case per annum direct cost and indirect
cost amounted to US$862.81 (33.4%) and US$1723.40
(66.6%) respectively. Direct medical cost was US$714.86,
it was the great majority of direct cost, direct non-medical
cost was only 5.8% of total cost. Cost due to lost working-
days and disability was the great majority of indirect cost.
Indirect cost can be split up patients’ (39.1%) and care-
givers’ (25.6%) cost. We have not found suicide cases be-
cause of the researcher methods, objective reasons and
the traditional idea of Chinese and culture background in
China, hence mortality cost was 0. Value of damaged
properties was US$49.63 (1.9%).
Comparison of costs between out-patients and in-
patients
The comparison of costs between out-patients and in-
patients are given in Table 3.
Table 2 The per case per annum total cost, direct cost,
indirect cost (US$)
Costs components x ±SD % of total costs
Total cost 2586.21 ± 1343.08 100
1. Direct cost 862.81 ± 739.74 33.4
(1) Direct medical cost 714.86 ± 706.64 27.6
(2) Direct non-medical cost 147.95 ± 153.36 5.8
2. Indirect cost 1723.40 ± 1056.90 66.6
(1) Value of damaged properties 49.63 ± 109.61 1.9
(2) Cost due to lost working-days
and disability
1673.77 ± 1048.42 64.7
Patients 1009.84 ± 708.21 39.1
Caregivers 663.93 ± 734.79 25.6
(3) Mortality cost 0(no suicide case) 0
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that the per case total cost, direct cost and direct-
medical cost of in-patients were more higher than out-
patients (P < 0.05). There was no difference in other cost
between in-patients and out-patients (P > 0.05).
Comparison of cost between urban-patients and rural-
patients
Comparison of cost between urban-patients and rural-
patients are given in Table 4.
With non-parameter Mann–Whitney U test, we found
that the per case total cost, direct cost, direct medical cost
and cost due to lost working day and disability of urban-
patients were more higher than rural-patients (P < 0.05).
There was no difference in other cost between in-patients
and out-patients (P > 0.05).
Service utilization of per patient
Direct medical cost of per out-patient visit was US$
57.57, average annual visit times were 5, direct medical
cost of in-patient per day was US$21.91, average annual
hospitalization days were 34, 212 working-days were lost
in one year (patient 129 days and caregivers 83 days).Table 3 Comparison of cost between out-patients and in-pati
Costs components Out-patients (n =
Total cost 2008.08 ± 1012.00
1. Direct cost 406.38 ± 311.13
(1) Direct medical cost 267.70 ± 255.66
(2 ) Direct non-medical cost 138.68 ± 114.58
2. Indirect cost 1601.70 ± 956.10
(1) Value of damaged properties 65.49 ± 128.86
(2) Costs due to lost working days and disability 1536.21 ± 956.77
Patients 936.48 ± 647.62
Caregivers 599.73 ± 702.85Multivariate regression analysis
Table 5 shows the results of multivariate regression
analysis. Five variables were significantly correlated with
higher cost: professional status (cadre), diagnostic subtype
(residual schizophrenia), urban/rural patients (urban pa-
tients), in-patients/ (in-patients), and researcher centre
(southern center). The standardized regression coefficient
were 0.308, 0.218, 0.212, 0.156 and 0.149 respectively,
the correlation of determination R square was 0.2741,
F = 15.651, P < 0.0000. These characteristics explain 27.41%
of the variability in the total cost.
Discussion
The burden of schizophrenia is large and multifaceted.
Economic costs are one of the most important compo-
nents. This study provided an overall estimate of the
costs of schizophrenia, but it can not capture all costs,
as noted by other researchers, two types of the costs
were always underestimated: the cost to families and the
costs of publicly owned capital.
In the present study, the sample were selected from
two areas, one of which was from northern China and
another was from southern China, the two centers were
not selected randomly, hence, the results of the study
reflected only the cost of schizophrenia in two areas of
China. Centers taking part in were located in the north
and south of China, but none in the west and east of the
country. The sample seems not to be representative of
the cost of schizophrenic patients in China (mainland).
The sample was not quite large, only patients, not centre,
were randomly selected, and only two centers were se-
lected. We have not found suicide cases, however, the cost
due to suicide are the important parts.
We study the economic cost of schizophrenia with hu-
man capital approach(HCP), however, HCP has many
limitations, it has many assumptions that are not likely
to hold, e.g. it assumes that there is full employment.
Goeree [20] valuated the productivity costs due to pre-
mature mortality and compared the human capital ap-
proach and friction cost (FC) methods for schizophrenia.ents(US$, x ±SD)
156) In-patients (n = 143) U value P value
3116.17 ± 1392.41 5437.50 0.000
1281.21 ± 771.36 2149.50 0.000
1124.77 ± 739.30 1568.00 0.000
156.44 ± 161.36 10694.00 0.538
1835.00 ± 1133.11 10004.00 0.124
35.11 ± 86.28 10018.00 0. 108
1799.86 ± 1114.08 9694.00 0.051
1077.09 ± 755.34 10079.50 0.150
722.77 ± 760.37 10031.00 0.132
Table 4 Comparison of cost between urban-patients and rural-patients(US$, x ±SD)
Costs components Rural-patients (n = 181) Urban-patients (n = 118) U value p value
Total cost 2383.90 ± 1184.40 2761.97 ± 1447.91 9333.00 0.017
1. Direct cost 776.71 ± 731.84 937.61 ± 740.70 9237.50 0.012
(1) Direct medical cost 638.61 ± 699.67 781.11 ± 708.16 9272.50 0.013
(2) Direct non-medical cost 138.10 ± 152.69 156.50 ± 153.91 10450.00 0.369
2. Indirect cost 1607.19 ± 927.49 1824.37 ± 1151.03 9941.50 0.114
(1) Value of damaged properties 40.69 ± 87.94 57.41 ± 125.20 10678.50 0.531
(2) Costs due to lost working days and disability 1566.50 ± 901.61 1766.96 ± 1157.76 10101.50 0.172
Patients 878.54 ± 584.02 1123.91 ± 784.75 9093.50 0.007
Caregivers 687.96 ± 718.58 643.05 ± 750.21 10314.50 0.279
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the human capital approach are substantially higher than
those obtained from the FC method. In circumstances of
unemployment, the human capital approach is an over-
estimate of future productivity losses for premature mor-
tality. All the limitations mentioned-above must be
borne in mind.
Despite these limitation, the results from the present
study show that schizophrenia cause a substantial eco-
nomic burden to healthcare systems, community, other
caregivers and society. The per case per annum total cost,
direct cost and indirect cost amounted to US$2586.21, US
$862.81 (33.4%) and US$1723.40 (66.6%) respectively. In-
direct costs were the great majority of the economic cost
of schizophrenia. In the indirect cost, cost due to lost
working days and disability were the great majority.
Schizophrenia is correlated to loss of working days, lack of
well-being and poor levels of social functioning. Theses
are the main results drawn from the analysis of indirect
costs that appear to be exclusively borne by patients, care-
givers and ultimately society as a whole. These findings
are consistent with the majority of results of other cost of
illness studies on schizophrenia where indirect costs vary
from 48% to 86.5% of total cost [21-24]. Hence we must
pay close attention to the indirect of the cost of schizo-
phrenia, take effective measure to improve the social func-




Professional status 0.033 0.006
Diagnostic subtype 0.037 0.009
Urban/rural patients 0.098 0.027
In-patients/out-patients 0.072 0.024
Researcher centre 0.074 0.025
Constant 3.752 0.056
aR square, 0.274; F, 15.651; P < 0.0000; n = 299.China is a large developing country, the per case pure
income of rural residents was about US$450, about 60%
patients of our sample were peasants, students or un-
employed, the total cost, amounted to US$2586.21, was
heavy for them and their families who had been very
poor because of the chronic illness.
A study carried out by Andlin-Sobock [19] shown that
the cost per case of schizophrenia differs significantly
across the different country in Europe, range from €2360
(Estonia) to €13862 (Switzerland). In every country, the
cost per case of schizophrenia was higher than other men-
tal illness. Their findings shown that the cost per case of
schizophrenia differs between countries and are highest in
countries with the highest national income and healthcare
expenditure. This explains the estimated lower cost per
case in China. In comparison with European countries,
condition with relatively low cost, in schizophrenia, was
associated with the lower level of economy development.
The total cost, direct cost and direct medical cost of
per case of in-patients was higher than out-patients of
schizophrenia. The reason, might be stated that the med-
ical model in China was different from other countries.
There are various medical model for the management of
schizophrenia such as day-care center, day-hospital, patient-
s’home, community mental health centers (CMHCs), shel-
tered workshops, psychiatric ambulatories and national
health service as well in developed countries [18]. Howeveror Standardized
coefficients
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home to take medicine except for hospitalization in mental
hospital and seeing doctor in out-patient, have no other
choice. During hospitalization in mental hospital patients
could receive various kinds of treatments, hence the direct
medical cost, direct cost, total cost will increase. During
non-hospitalization patients receive no treatment except
for drug therapy, hence all kinds of cost will decrease.
There was significant difference in per case per annum
total cost, direct cost, direct medical cost, cost due to
lost working-days and disability of patients between
urban and rural schizophrenic patients, the former is
higher than the latter. In China, expensive new antipsy-
chotics were mainly applied to urban patients but few to
rural patients, drug cost was the main part of direct
medical cost to a turn, lead to the increase of direct cost
and total cost. Cost due to lost working days and disabil-
ity of urban patients are higher than rural patients
because the economic income of urban residents was
higher than rural residents in China.
Multivariate regression analysis shows that cadre pro-
fessional, paranoid type schizophrenia, urban patients,
in-patients and southern researcher centre were corre-
lated with higher total costs.
The reason why the cost of urban patients and in-
patients were higher is in line with the explanation above.
Cadres (civil servants) are a special population with higher
economic level in China. In general, their income was
higher than peasants and people being unemployed, they
would pay more money to the treatment of schizophrenia.
It is differs from the finding of Percudani in Italy [11,25],
they found being unemployed was associated with higher
service cost. Percudani also found that the total cost per
patients differ wildly according to whether patients had
been hospital during the observation period. Patients with
a previous psychiatric contact and a longer duration of ill-
ness were more costly than the other patients [11,25].
Similar with cadres (civil servants), most urban schizo-
phrenic patients had regular income, good family eco-
nomic condition, more medical knowledge and saw
doctros in the early stage of the illness. They usually took
new and expensive medicine. Conversely, most rural pa-
tients were peasants or people being unemployed, they
had lower economic income and poor family economic
condition, they could not afford to enormous economic
pressure. These patients could not be hospitalized in time
and they usually took cheaper medicine, so their costs
were lower. Residual type schizophrenic patients had
longer duration of illness and poor prognosis, with more
difficulties in treatment and rehabilitation and higher
probability of hospitalization, so their costs were higher.
The reason why southern researcher centre correlated
with higher costs was complex. The main reason was as-
sociated with economic development.Economic cost was a complex index which was af-
fected by many factors, not just related with the medical
factors. In addition to the five factors getting into the re-
gression equation, there were a lot of other factors influ-
encing the economic cost of the schizophrenic patients.
So the five factors can only explain the dependent vari-
able (total economic costs) 27.41%, other factors and ac-
cidental factors accounted for 72.59%.
Conclusion
The major strengths of this study are that of having
clearly showed that (i) the economic burden of schizo-
phrenia was serious in China, (ii) the highest proportion
of the economic cost of schizophrenia was indirect cost,
the cost of urban patients are more higher than the cost
of rural patients, the cost of in-patients are more higher
than the cost of out-patients; (iii) We must pay close at-
tention to the economic burden of schizophrenia.
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